# A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

> **NCT06365853** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer
- Folate Receptor-Alpha Positive

## Interventions

- **DRUG:** Mirvetuximab Soravtansine
- **DRUG:** Lubricating Eye Drops
- **DRUG:** Prednisolone acetate ophthalmic suspension 1% eye drops
- **DRUG:** Brimonidine tartrate ophthalmic solution eye drops

## Key facts

- **NCT ID:** NCT06365853
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365853, "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06365853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*